Radical treatment for blastomycosis following unsuccessful liposomal amphotericin
Copyright © 2022 Elsevier Ltd. All rights reserved..
Pulmonary blastomycosis is a respiratory disease that is caused by the fungus Blastomyces spp, which is acquired through inhalation of the fungal spores. Blastomycosis is relatively uncommon, with yearly incidence rate of 1-2 cases per 100 000 people. Blastomycosis is a disease that is endemic to the midwest and southern regions of the USA, most commonly affecting immunocompromised patients. About 50% of patients are asymptomatic, but for those who progress to acute respiratory distress syndrome (ARDS) mortality can be as high as 80%. Patients with severe blastomycosis are initially treated with intravenous amphotericin B, followed by long-term itraconazole maintenance therapy. In this Grand Round, we present the case of an immunocompetent 35-year-old man diagnosed with chronic pulmonary blastomycosis who had a poor response to 10 days of intravenous liposomal amphotericin B (L-AmB). He was endotracheally intubated and eventually cannulated for extracorporeal membrane oxygenation (ECMO), due to worsening respiratory function. L-AmB was replaced with a continuous infusion of intravenous amphotericin B deoxycholate (AmB-d). He improved significantly and was decannulated from ECMO on day 9 of AmBd continuous infusion and extubated on day 12 Although L-AmB is considered first-line treatment for blastomycosis, mortality remains high for patients with ARDS associated with blastomycosis. This case highlights the importance of considering AmB-d continuous infusions for patients with severe blastomycosis who might have poor clinical responses to L-AmB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
The Lancet. Infectious diseases - 22(2022), 12 vom: 30. Dez., Seite e377-e381 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chew, Christopher [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7XU7A7DROE |
|---|
| Anmerkungen: |
Date Completed 29.11.2022 Date Revised 09.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1473-3099(22)00352-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343300796 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343300796 | ||
| 003 | DE-627 | ||
| 005 | 20231226020125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(22)00352-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343300796 | ||
| 035 | |a (NLM)35809592 | ||
| 035 | |a (PII)S1473-3099(22)00352-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chew, Christopher |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radical treatment for blastomycosis following unsuccessful liposomal amphotericin |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2022 | ||
| 500 | |a Date Revised 09.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Pulmonary blastomycosis is a respiratory disease that is caused by the fungus Blastomyces spp, which is acquired through inhalation of the fungal spores. Blastomycosis is relatively uncommon, with yearly incidence rate of 1-2 cases per 100 000 people. Blastomycosis is a disease that is endemic to the midwest and southern regions of the USA, most commonly affecting immunocompromised patients. About 50% of patients are asymptomatic, but for those who progress to acute respiratory distress syndrome (ARDS) mortality can be as high as 80%. Patients with severe blastomycosis are initially treated with intravenous amphotericin B, followed by long-term itraconazole maintenance therapy. In this Grand Round, we present the case of an immunocompetent 35-year-old man diagnosed with chronic pulmonary blastomycosis who had a poor response to 10 days of intravenous liposomal amphotericin B (L-AmB). He was endotracheally intubated and eventually cannulated for extracorporeal membrane oxygenation (ECMO), due to worsening respiratory function. L-AmB was replaced with a continuous infusion of intravenous amphotericin B deoxycholate (AmB-d). He improved significantly and was decannulated from ECMO on day 9 of AmBd continuous infusion and extubated on day 12 Although L-AmB is considered first-line treatment for blastomycosis, mortality remains high for patients with ARDS associated with blastomycosis. This case highlights the importance of considering AmB-d continuous infusions for patients with severe blastomycosis who might have poor clinical responses to L-AmB | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a liposomal amphotericin B |2 NLM | |
| 650 | 7 | |a Amphotericin B |2 NLM | |
| 650 | 7 | |a 7XU7A7DROE |2 NLM | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Thapa, Nikhilesh |e verfasserin |4 aut | |
| 700 | 1 | |a Ogbuagu, Henry |e verfasserin |4 aut | |
| 700 | 1 | |a Varghese, Merin |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Dhaval |e verfasserin |4 aut | |
| 700 | 1 | |a Abbas, Raza |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Teshome, Molla |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammed, Khaja |e verfasserin |4 aut | |
| 700 | 1 | |a Saleem, Sohail |e verfasserin |4 aut | |
| 700 | 1 | |a Aggarwal, Deepak |e verfasserin |4 aut | |
| 700 | 1 | |a Barns, Barry |e verfasserin |4 aut | |
| 700 | 1 | |a McDonald, April |e verfasserin |4 aut | |
| 700 | 1 | |a Ormenisan-Gherasim, Claudia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Infectious diseases |d 2001 |g 22(2022), 12 vom: 30. Dez., Seite e377-e381 |w (DE-627)NLM117564362 |x 1474-4457 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:12 |g day:30 |g month:12 |g pages:e377-e381 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1473-3099(22)00352-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 12 |b 30 |c 12 |h e377-e381 | ||